含有反感性寡核酸的纳米酶通过声基因代谢疗法逆转瘤免疫抑制
Bing Xiong1, Jifeng Yu2, Congjian Wen2
1Shanghai Institute of Medical Imaging, Shanghai 200032, PR China; Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China; Institute of Medical Ultrasound and Engineering, Fudan University, Shanghai 200032, PR China.
概括
这项研究提出了一种新的声基因疗法,可以激活抗瘤免疫力,并通过向CD73.3来降低免疫抑制性腺. 这种方法抑制了瘤的生长,并建立了长期的免疫记忆.
科学领域:
- 生物医学工程 生物医学工程
- 癌症 免疫疗法 免疫疗法
- 代谢重编程 代谢重编程
背景情况:
- 免疫抑制性腺,由缺氧诱导的CD73升高,阻碍了抗瘤免疫反应.
- 向腺代谢对于有效的癌症免疫疗法至关重要.
研究的目的:
- 开发一种声基因代谢疗法,可以激活免疫细胞死亡 (ICD),同时抑制腺的产生.
- 设计一个多功能金属有机框架 (MOF) 用于向癌症治疗.
主要方法:
- 装载着 (Ru) 单原子催化剂和针对CD73mRNA的反意义寡核酸 (ASO) 的MOF的制造.
- 使用超声波触发ROS生成以通过溶酶体逃逸传递ICD和ASO.
- 使用Ru催化剂将瘤H2O2转化为O2,缓解缺氧并增强声动疗法.
主要成果:
- MOF系统有效地缓解了瘤缺氧,并通过声动疗法诱导了ICD.
- ASO输送成功降低了CD73的表达,抑制了腺的产生,抑制了瘤的生长.
- 该疗法建立了长期免疫记忆,防止小鼠的肺转移.
结论:
- 开发的声基因代谢疗法通过重编程瘤微环境,显示出癌症治疗的巨大潜力.
- 这种方法为基于寡核酸的疗法提供了一个新的策略,这对代谢疾病的治疗有意义.
相关概念视频
siRNA - Small Interfering RNAs
18.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


